DrugRisk Update: Latest Yaz Settlement Amounts Released This Week

Share Article

The Drug Resource Center is the premiere source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com.

yaz lawsuit
In DrugRisk legal news, Bayer also indicated they began settling Yaz lawsuits last spring, spending as much as $750 million to settle up to 3,500 cases by the end of the 3rd Quarter in 2012.

The birth control safety advocates at DrugRisk.com are alerting those who have taken the oral contraceptives Yaz or Yasmin that new information will be added this week showing how many Yaz lawsuits Bayer has settled, how much they have paid, and what type of cases they are settling.

“DrugRisk’s goal is to improve consumer safety through education of the latest drug warnings, recalls, studies and litigation news. We receive calls every day from patients concerned over blood clot side effects and whether Bayer is still compensating victims,” explains DrugRisk representative Ryan Mayer.

The resource center contains studies from the British Medical Journal and FDA which warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.*

In previous financial information uncovered by DrugRisk, Bayer admitted more than 12,000 women taking Yaz or Yasmin had filed a Yaz lawsuit over side effects like DVT and pulmonary embolism.**

Due to the number of patients filing a claim, they were consolidated to a special federal Multi-District Litigation court in Illinois. The case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

In DrugRisk legal news, Bayer also indicated they began settling Yaz lawsuits last spring, spending as much as $750 million to settle up to 3,500 cases by the end of the 3rd Quarter in 2012.**

Now, the latest information showing the number of cases, how many have settled and what Bayer has spent will be released on Thursday, February 28 as the 2012 full year and 4th quarter financial statements are published.***

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

DrugRisk cautions that patients should seek a lawyer with experience in Yaz litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
**Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012
***investor.bayer.de/en/events/live-events/fyq4-2012-conference-call/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
DrugRisk
888-415-1859
Email >
Visit website